A broad-spectrum SARS-CoV-2 RBD vaccine with selected high-impact mutations and novel adjuvant induces durable T cell response and broad protection in mice
Rationally designed with key high-impact mutation sites, M5-RBD effectively overcomes SARS-CoV-2 variant immune evasion and elicits broad-spectrum neutralizing antibodies. The combination with HP007 adjuvant enhances immune protection, providing a promising strategy for the development of next-generation COVID-19 vaccines.
Authors
- Hongyun Zhao (ORCID: https://orcid.org/0000-0002-1251-3888)
- Jiejie Liu (ORCID: https://orcid.org/0009-0006-5442-6471)
- X Chen
- Shimin Yang
- Jiangpeng Feng
- M. J. Guo
- Jianzhong Chen (ORCID: https://orcid.org/0000-0002-8232-7298)
- Weiyi Yu
- Huan Yan (ORCID: https://orcid.org/0009-0008-1810-4920)
- Yuehua Chen (ORCID: https://orcid.org/0009-0006-1343-7449)
- Shengnan Qian
- Ke Lan
- Qianyun Liu
- Zhen Zhang
- Xin Wang
- Yuzhen Zhang
- Chengbao Ma
- Li Zhou
Institutions
- Wuhan Institute of Virology (CN)
- Jiangsu T-mab BioPharma (China) (CN)
Publication Details
- Journal
- Frontiers in Cellular and Infection Microbiology
- Published
- 2026-01-30
- DOI
- https://doi.org/10.3389/fcimb.2025.1690554
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- China Postdoctoral Science Foundation
- Natural Science Foundation of Hubei Province